Search

Your search keyword '"Loumaye, E."' showing total 251 results
Start Over Author "Loumaye, E."
251 results on '"Loumaye, E."'

12. Successful induction of ovulation and completed pregnancy using recombinant human luteinizing hormone and follicle stimulating hormone in a woman with Kallmann's syndrome

Author

Kousta, E., White, D.M., Piazzi, A., Loumaye, E., Franks, S., Kousta, E., White, D.M., Piazzi, A., Loumaye, E., and Franks, S.

Abstract

The induction of ovulation in women with hypogonado-trophic hypogonadism requires follicle stimulating hormone (FSH) for follicular growth and both FSH and luteinizing hormone (LH) to induce optimal follicular steroidogenesis. The development of human recombinant FSH and LH means that individually tailored doses of both hormones can be used with the aim of inducing unifollicular ovulation. This report describes the use of recombinant human FSH and LH for the induction of ovulation and conception in the second cycle of treatment, and subsequently a successfully completed pregnancy in a woman with Kallmann's syndrome

Published
2017

13. Ulipristal acetate versus leuprolide acetate for uterine fibroids

Author

Donnez, J, Tomaszewski, J, Vázquez, F, Bouchard, P, Lemieszczuk, B, Baró, F, Nouri, K, Selvaggi, L, Sodowski, K, Bestel, E, Terrill, P, Osterloh, I, Loumaye, E, the PEARL II Study Group, MILANI, RODOLFO, Donnez, J, Tomaszewski, J, Vázquez, F, Bouchard, P, Lemieszczuk, B, Baró, F, Nouri, K, Selvaggi, L, Sodowski, K, Bestel, E, Terrill, P, Osterloh, I, Loumaye, E, Milani, R, the PEARL II Study, G, Vázquez, F, Baró, F, PEARL II Study Group, and PERINO, A

Subjects
Adult, medicine.medical_specialty, Uterine fibroids, Intention to Treat Analysi, Urology, Administration, Oral, Endometrium, Injections, Intramuscular, law.invention, chemistry.chemical_compound, Young Adult, Primary outcome, Randomized controlled trial, Double-Blind Method, law, Ulipristal acetate, Selective progesterone receptor modulator, medicine, Uterine Neoplasm, Ulipristal, Menorrhagia, Gynecology, Intention-to-treat analysis, Leiomyoma, business.industry, Obstetrics and Gynecology, Uterine bleeding, Uterine fibroids, uterine leiomyomas, uterine bleeding, ulipristal acetate, leuprolide acetate, medical therapy, General Medicine, Norpregnadiene, Middle Aged, medicine.disease, Settore MED/40 - Ginecologia E Ostetricia, medicine.anatomical_structure, chemistry, Amenorrhea, Female, medicine.symptom, Leuprolide, business, Human
Abstract

A b s t r ac t Background The efficacy and side-effect profile of ulipristal acetate as compared with those of leuprolide acetate for the treatment of symptomatic uterine fibroids before surgery are unclear. Methods In this double-blind noninferiority trial, we randomly assigned 307 patients with symptomatic fibroids and excessive uterine bleeding to receive 3 months of daily therapy with oral ulipristal acetate (at a dose of either 5 mg or 10 mg) or once-monthly intramuscular injections of leuprolide acetate (at a dose of 3.75 mg). The primary outcome was the proportion of patients with controlled bleeding at week 13, with a prespecified noninferiority margin of −20%. Results Uterine bleeding was controlled in 90% of patients receiving 5 mg of ulipristal acetate, in 98% of those receiving 10 mg of ulipristal acetate, and in 89% of those receiving leuprolide acetate, for differences (as compared with leuprolide acetate) of 1.2 percentage points (95% confidence interval [CI], −9.3 to 11.8) for 5 mg of ulipristal acetate and 8.8 percentage points (95% CI, 0.4 to 18.3) for 10 mg of ulipristal acetate. Median times to amenorrhea were 7 days for patients receiving 5 mg of ulipristal acetate, 5 days for those receiving 10 mg of ulipristal acetate, and 21 days for those receiving leuprolide acetate. Moderate-to-severe hot flashes were reported for 11% of patients receiving 5 mg of ulipristal acetate, for 10% of those receiving 10 mg of ulipristal acetate, and for 40% of those receiving leuprolide acetate (P

Published
2012

14. Ulipristal acetate versus leuprolide acetate for uterine fibroids

Author

Donnez J., Tomaszewski J., Vaszquez F., Bouchard P., Lemieszczuk B., Barò F., Nouri K., Selvaggi L., Sodowski K., Bestel E., Terrill P., Osterloh I., Loumaye E., Barlow D. H., Barri P. N., Bergeron C., Bornstein J., Caraco Y., Carmona F., Caruso A., Diedrich K., Donnez O., Fauser B. C., Ferenczy A., Gilabert J., Giuliani A., Glezerman M., Goettker Schnetmann W., Hillemanns P., Huber J., Jimenez J. S., Kay R., Kiesel L., Kotarski J., Layani L., Mannering M., Marshall J., Martinez S., McPherson K., Melis G. B., Milani R., Morris E., Nisolle M., Palacios S., Parrilla J. J., Paul N. W., Pawlaczyk A., Pellicer A., Perino A., Vazquez F., Williams A. R., de Ziegler D., NAPPI, CARMINE, Donnez, J., Tomaszewski, J., Vaszquez, F., Bouchard, P., Lemieszczuk, B., Barò, F., Nouri, K., Selvaggi, L., Sodowski, K., Bestel, E., Terrill, P., Osterloh, I., Loumaye, E., Barlow, D. H., Barri, P. N., Bergeron, C., Bornstein, J., Caraco, Y., Carmona, F., Caruso, A., Diedrich, K., Donnez, O., Fauser, B. C., Ferenczy, A., Gilabert, J., Giuliani, A., Glezerman, M., Goettker Schnetmann, W., Hillemanns, P., Huber, J., Jimenez, J. S., Kay, R., Kiesel, L., Kotarski, J., Layani, L., Mannering, M., Marshall, J., Martinez, S., Mcpherson, K., Melis, G. B., Milani, R., Morris, E., Nappi, Carmine, Nisolle, M., Palacios, S., Parrilla, J. J., Paul, N. W., Pawlaczyk, A., Pellicer, A., Perino, A., Vazquez, F., Williams, A. R., and de Ziegler, D.

Subjects
myoma, fibroid, ulipristal
Published
2012

15. Recombinant hCG (OVIDRELTM) and recombinant Interferon-β1a (REBIF®) (No. 13 in a series of articles to promote a better understanding of the use of genetic engineering)

Author

Loumaye E and Fonjallaz P

Subjects
Clinical Trials as Topic, business.industry, Bioengineering, CHO Cells, General Medicine, Computational biology, Protein Engineering, Bioinformatics, Chorionic Gonadotropin, Applied Microbiology and Biotechnology, Recombinant Proteins, law.invention, law, Cricetinae, Recombinant DNA, Animals, Humans, Medicine, Female, business, Infertility, Female, Biotechnology, Recombinant interferon beta-1a
Published
2001
Full Text
View/download PDF

18. Recombinant Human Luteinizing Hormone is as effective as, but safer than urinary human chorionic gonadotropin in inducing final follicular maturation and ovulation in in vitro procedures: results of a multicenter double-blind study

Author

Engrand P, Arguinzoniz, Piazzi A, Loumaye E, Devroey P, Smith J, Andersen AN, Frydman, Hedon B, Hugues JN, Roulier R, Salat Baroux J, Homburg R, Shoham Z, Barash A, Palermo R, Flamigni C, Schoemaker J, Te Velde E. R, Braat D, Hamberger L, Germond M, Imthurn B, Barlow DH, Brisden P, Fleming R, Hull M, Lockwood G, Templeton A, Yates R., PORCU, ELEONORA, Engrand P, Arguinzoniz, Piazzi A, Loumaye E, Devroey P, Smith J, Andersen AN, Frydman, Hedon B, Hugues JN, Roulier R, Salat Baroux J, Homburg R, Shoham Z, Barash A, Palermo R, Flamigni C, Porcu E, Schoemaker J, Te Velde E R, Braat D, Hamberger L, Germond M, Imthurn B, Barlow DH, Brisden P, Fleming R, Hull M, Lockwood G, Templeton A, and Yates R

Subjects
Human gonadotropin, endocrine system, Human Luteinizing Hormone
Abstract

n a prospective, comparative, dose-finding study, the minimal effective dose of recombinant human LH (rhLH) required to induce final follicular maturation and early luteinization in patients undergoing in vitro fertilization and embryo transfer was determined. In addition, the efficacy and safety of rhLH were compared with urinary human CG (u-hCG). A total of 259 infertile women, aged 18-39 yr, were enrolled in the study. After pituitary desensitization using a GnRH agonist, rhFSH was administered for ovarian stimulation. Patients then received either rhLH or u-hCG to achieve final follicular maturation. The doses of rhLH administered were 5,000, 15,000, 30,000, or 15,000 + 10,000 IU (second injection administered 3 days after the first injection; 129 patients), and those of u-hCG were consistently 5,000 IU (121 patients). Ovum pick-up was performed 34--38 h after rhLH or u-hCG injection. After fertilization in vitro, up to three embryos were replaced in the uterine cavity. The numbers of oocytes retrieved after u-hCG or rhLH administration were not significantly different between the four different doses of rhLH, when compared with each corresponding u-hCG group, nor when compared with the pool of all u-hCG groups. Similarly, there were no statistically significant differences in: the number of oocytes retrieved per follicle with a diameter of over 10 mm on the day of u-hCG or rhLH administration; the number of patients with at least one oocyte retrieved; oocyte nuclear maturity; oocyte potential for fertilization; the number of embryos; the number of total, biochemical, and clinical pregnancies; and the embryo implantation rate. However, in many of these parameters, the lowest dose of rhLH seemed suboptimal when compared with the higher dose. In terms of safety, rhLH was well tolerated at a dose of up to 30,000 IU. Moderate ovarian hyperstimulation syndrome (OHSS) was reported in 12.4% of patients who received u-hCG and 12.0% of patients who received two injections of rhLH. No moderate or severe OHSS was reported in patients who received a single dose of rhLH up to 30,000 IU. The results show that a single dose of rhLH is effective in inducing final follicular maturation and early luteinization in in vitro fertilization and embryo transfer patients and is comparable with 5,000 IU u-hCG. A single dose of rhLH results in a highly significant reduction in OHSS compared with hCG. The dose of rhLH giving the highest efficacy to safety ratio was between 15,000 and 30,000 IU

Published
2004

19. The crystal structure of the C45S mutant of annelid Arenicola marina peroxiredoxin 6 supports its assignment to the mechanistically typical 2-Cys subfamily without any formation of toroid-shaped decamers

Author

Smeets, A., Loumaye, E., Clippe, A., Rees, J.-F., Knoops, B., and Declercq, J.-P.

Subjects
Arenicola marina [Lugworm]
Abstract

The peroxiredoxins (PRDXs) define a superfamily of thiol-dependent peroxidases able to reduce hydrogen peroxide, alkyl hydroperoxides, and peroxynitrite. Besides their cytoprotective antioxidant function, PRDXs have been implicated in redox signaling and chaperone activity, the latter depending on the formation of decameric high-molecular-weight structures. PRDXs have been mechanistically divided into three major subfamilies, namely typical 2-Cys, atypical 2-Cys, and 1-Cys PRDXs, based on the number and position of cysteines involved in the catalysis. We report the structure of the C45S mutant of annelid worm Arenicola marina PRDX6 in three different crystal forms determined at 1.6, 2.0, and 2.4 Å resolution. Although A. marina PRDX6 was cloned during the search of annelid homologs of mammalian 1-Cys PRDX6s, the crystal structures support its assignment to the mechanistically typical 2-Cys PRDX subfamily. The protein is composed of two distinct domains: a C-terminal domain and an N-terminal domain exhibiting a thioredoxin fold. The subunits are associated in dimers compatible with the formation of intersubunit disulfide bonds between the peroxidatic and the resolving cysteine residues in the wild-type enzyme. The packing of two crystal forms is very similar, with pairs of dimers associated as tetramers. The toroid-shaped decamers formed by dimer association and observed in most typical 2-Cys PRDXs is not present. Thus, A. marina PRDX6 presents structural features of typical 2-Cys PRDXs without any formation of toroid-shaped decamers, suggesting that it should function more like a cytoprotective antioxidant enzyme or a modulator of peroxide-dependent cell signaling rather than a molecular chaperone.

Published
2008

22. Inhibition of steroid sulfatase decreases endometriosis in an in vivo murine model.

Author

UCL - SSS/IREC/GYNE - Pôle de Gynécologie, UCL - (SLuc) Service de gynécologie et d'andrologie, Colette, Sébastien, Defrere, Sylvie, Lousse, Jean-Christophe, Van Langendonckt, Anne, Gotteland, J.P., Loumaye, E., Donnez, Jacques, UCL - SSS/IREC/GYNE - Pôle de Gynécologie, UCL - (SLuc) Service de gynécologie et d'andrologie, Colette, Sébastien, Defrere, Sylvie, Lousse, Jean-Christophe, Van Langendonckt, Anne, Gotteland, J.P., Loumaye, E., and Donnez, Jacques

Abstract

Steroid sulfatase (STS) is involved in estrogen biosynthesis and expressed in eutopic and ectopic endometrium of disease-free and endometriosis patients. The present study was designed to investigate its role in endometriosis development.

Published
2011

23. Session 71: Surgery

Author

Papadopoulos, S., primary, Venetis, C. A., additional, Grimbizis, G., additional, Tarlatzis, B. C., additional, Rustamov, O., additional, Krishnan, M., additional, Roberts, S., additional, Fitzgerald, C., additional, Calis, P. T., additional, Sokmensuer, L. K., additional, Bozdag, G., additional, Fauser, B., additional, Oliver, J., additional, Loumaye, E., additional, Kozachenko, I., additional, Adamyan, L., additional, and Makyan, Z., additional

Published
2013
Full Text
View/download PDF

25. Contribution to more patient-friendly ART treatment: efficacy of GnRH agonist as luteal support: results of a prospective, randomized, comparative study

Author

UCL - Cliniques universitaires Saint-Luc, UCL - MD/GYPE - Département de gynécologie, d'obstétrique et de pédiatrie, Loumaye, E., Pirard, Céline, Donnez, Jacques, 23rd Annual Meeting of the European-Society-of-Human-Reproduction-and-Embryology, UCL - Cliniques universitaires Saint-Luc, UCL - MD/GYPE - Département de gynécologie, d'obstétrique et de pédiatrie, Loumaye, E., Pirard, Céline, Donnez, Jacques, and 23rd Annual Meeting of the European-Society-of-Human-Reproduction-and-Embryology

Published
2007

26. [Clinical use of recombinant gonadotropins (FSH, LH, hCG)]

Author

Jm, Antoine, Loumaye E, Alvarez S, Philippe Merviel, Cornet D, Mandelbaum J, and Salat-Baroux J

Subjects
Adult, Ovulation Induction, Pregnancy, Pregnancy Outcome, Humans, Female, Fertilization in Vitro, Follicle Stimulating Hormone, Luteinizing Hormone, Chorionic Gonadotropin, Infertility, Female, Recombinant Proteins
Abstract

The production of recombinant gonadotropins is independent of urine collection. They have a high specific activity and a better batch to batch consistency than urinary gonadotropins. In our IVF programme 62 normo-ovulatory patients less than 38 years old, with tubal or idiopathic infertility and normal sperm, were treated by r-FSH and randomized into four groups : with or without LHRH agonist, step-up or step-down stimulation. The overall results were higher in the agonist groups, but did not reveal any significant difference between step-up and step-down stimulation.

Published
1997

28. POSTER VIEWING SESSION - ENDOMETRIOSIS, ENDOMETRIUM, IMPLANTATION AND FALLOPIAN TUBE

Author

Palial, K. K., primary, Drury, J., additional, Heathcote, L., additional, Valentijin, A., additional, Farquharson, R. G., additional, Gazvani, R., additional, Rudland, P. S., additional, Hapangama, D. K., additional, Celik, N., additional, Celik, O., additional, Aktan, E., additional, Ozerol, E., additional, Celik, E., additional, Bozkurt, K., additional, Paran, H., additional, Hascalik, S., additional, Ozerol, I., additional, Arase, T., additional, Maruyama, T., additional, Uchida, H., additional, Miyazaki, K., additional, Oda, H., additional, Uchida-Nishikawa, S., additional, Kagami, M., additional, Yamazaki, A., additional, Tamaki, K., additional, Yoshimura, Y., additional, De Vos, M., additional, Ortega, C., additional, Smitz, J., additional, Van Vaerenbergh, I., additional, Bourgain, C., additional, Devroey, P., additional, Luciano, D., additional, Exacoustos, C., additional, Zupi, E., additional, Luciano, A. A., additional, Arduini, D., additional, Palomino, W. A., additional, Argandona, F., additional, Kohen, P., additional, Azua, R., additional, Scarella, A., additional, Devoto, L., additional, McKinnon, B., additional, Bersinger, N. A., additional, Mueller, M. D., additional, Bonavita, M., additional, Mattila, M., additional, Ferreira, F. P., additional, Maia-Filho, V., additional, Rocha, A. M., additional, Serafini, P., additional, Motta, E. L. A., additional, Kim, H., additional, Kim, C. H., additional, You, R. M., additional, Nah, H. Y., additional, Lee, J. W., additional, Kang, H. J., additional, Kang, B. M., additional, Letur - Koenirsch, H., additional, Haouzi, D., additional, Olivennes, F., additional, Rouleau, C., additional, Cohen-Bacri, P., additional, Dechaud, H., additional, Hamamah, S., additional, D'Hooghe, T., additional, Hummelshoj, L., additional, Dunselman, G. A. J., additional, Dirksen, C. D., additional, EndoCost Consortium, W. E. R. F., additional, Simoens, S., additional, Novembri, R., additional, Luisi, S., additional, Carrarelli, P., additional, Rocha, A. L. L., additional, Toti, P., additional, Reis, F. M., additional, Florio, P., additional, Petraglia, F., additional, Bruce, K. D., additional, Sadek, K. H., additional, Macklon, N., additional, Cagampang, F. R., additional, Cheong, Y., additional, Goudakou, M., additional, Kalogeraki, A., additional, Matalliotakis, I., additional, Papatheodorou, A., additional, Pasadaki, T., additional, Karkanaki, A., additional, Prapas, I., additional, Panagiotidis, I., additional, Kasapi, E., additional, Barlow, D., additional, Oliver, J., additional, Loumaye, E., additional, Khanmohammadi, M., additional, kazemnejad, S., additional, darzi, S., additional, Khanjani, S., additional, Zarnani, A., additional, Akhondi, M., additional, Tan, C. W., additional, Ng, C. P., additional, Loh, S. F., additional, Tan, H. H., additional, Choolani, M., additional, Griffith, L., additional, Chan, J., additional, Andersson, K. L., additional, Sundqvist, J., additional, Scarselli, G., additional, Gemzell-Danielsson, K., additional, Lalitkumar, P. G., additional, Jana, S., additional, Chattopadhyay, R., additional, Datta Ray, C., additional, Chaudhury, K., additional, Chakravarty, B. N., additional, Hannan, N., additional, Evans, J., additional, Hincks, C., additional, Rombauts, L. J. F., additional, Salamonsen, L. A., additional, Choi, D., additional, Lee, J., additional, Park, J., additional, Chang, H., additional, Kim, M., additional, Hwang, K., additional, Takeuchi, K., additional, Kurematsu, T., additional, Fukumoto, Y., additional, Yuki, Y., additional, Kuroki, Y., additional, Homan, Y., additional, Sata, Y., additional, Takeuchi, M., additional, Munoz Munoz, E., additional, Ortiz Olivera, G., additional, Fernandez Lopez, I., additional, Martinez Martinez, B., additional, Aguilar Prieto, J., additional, Portela Perez, S., additional, Pellicer Martinez, A., additional, Keltz, M., additional, Sauerbrun, M., additional, Breborowicz, A., additional, Gonzales, E., additional, Vicente-Munoz, S., additional, Puchades-Carrasco, L., additional, Morcillo, I., additional, Hidalgo, J. J., additional, Gilabert-Estelles, J., additional, Novella-Maestre, E., additional, Pellicer, A., additional, Pineda-Lucena, A., additional, Yavorovskaya, K. A., additional, Okhtyrskaya, T. A., additional, Demura, T. A., additional, Faizulina, N. M., additional, Ezhova, L. S., additional, Kogan, E. A., additional, Bilibio, J. P., additional, Souza, C. A. B., additional, Rodini, G. P., additional, Genro, V., additional, Andreoli, C. G., additional, de Conto, E., additional, Cunha-Filho, J. S. L., additional, Saare, M., additional, Soritsa, D., additional, Jarva, L., additional, Vaidla, K., additional, Palta, P., additional, Laan, M., additional, Karro, H., additional, Soritsa, A., additional, Salumets, A., additional, Peters, M., additional, Miskova, A., additional, Pilmane, M., additional, Rezeberga, D., additional, Assou, S., additional, Letur, H., additional, Piomboni, P., additional, Stendardi, A., additional, Gambera, L., additional, De Leo, V., additional, Focarelli, R., additional, Tamm, K., additional, Simm, J., additional, Metsis, M., additional, Vodolazkaia, A., additional, Fassbender, A., additional, Kyama, C. M., additional, Bokor, A., additional, Schols, D., additional, Huskens, D., additional, Meuleman, C., additional, Peeraer, K., additional, Tomassetti, C., additional, D'Hooghe, T. M., additional, Machens, K., additional, Afhuppe, W., additional, Schulz, A., additional, Diefenbach, K., additional, Schutt, B., additional, Faustmann, T., additional, Reischl, J., additional, Altmae, S., additional, Reimand, J., additional, Laisk, T., additional, Hovatta, O., additional, Kolde, R., additional, Vilo, J., additional, Stavreus-Evers, A., additional, Lee, J. H., additional, Kim, S. G., additional, Kim, Y. Y., additional, Park, I. H., additional, Sun, H. G., additional, Lee, K. H., additional, Ezoe, K., additional, Kawano, H., additional, Yabuuchi, A., additional, Ochiai, K., additional, Nagashima, H., additional, Osada, H., additional, Kagawa, N., additional, Kato, O., additional, Tamura, I., additional, Asada, H., additional, Taketani, T., additional, Tamura, H., additional, Sugino, N., additional, Garcia Velasco, J., additional, Prieto, L., additional, Quesada, J. F., additional, Cambero, O., additional, Toribio, M., additional, Hur, C. Y., additional, Lim, K. S., additional, Lee, W. D., additional, Lim, J. H., additional, Germeyer, A., additional, Nelson, L., additional, Graham, A., additional, Jauckus, J., additional, Strowitzki, T., additional, Lessey, B., additional, Gyulmamedova, I., additional, Illina, O., additional, Illin, I., additional, Mogilevkina, I., additional, Chaika, A., additional, Nosenko, O., additional, Boykova, I., additional, Gulmamedova, E., additional, Isik, H., additional, Moraloglu, O., additional, Seven, A. L. I., additional, Kilic, S., additional, Erkayiran, U., additional, Caydere, M., additional, Batioglu, S., additional, Alhalabi, M., additional, Samawi, S., additional, Taha, A., additional, Kafri, N., additional, Modi, S., additional, Khatib, A., additional, Sharif, J., additional, Othman, A., additional, Lancuba, S., additional, Branzini, C., additional, Lopez, M., additional, Baricalla, A., additional, Cristina, C., additional, Chen, J., additional, Jiang, Y., additional, Zhen, X., additional, Hu, Y., additional, Yan, G., additional, Sun, H., additional, Mizumoto, J., additional, Ueno, J., additional, Carvalho, F. M., additional, Casals, G., additional, Ordi, J., additional, Guimera, M., additional, Creus, M., additional, Fabregues, F., additional, Casamitjana, R., additional, Carmona, F., additional, Balasch, J., additional, Choi, Y. S., additional, Kim, K. C., additional, Kim, K. H., additional, Lee, B. S., additional, Kim, S. H., additional, Overbergh, L., additional, Verdrengh, E., additional, Kyama, C., additional, Waelkens, E., additional, Mathieu, C., additional, Iwasa, T., additional, Hatano, K., additional, Hasegawa, E., additional, Ito, H., additional, Isaka, K., additional, L. Rocha, A. L., additional, Reis, F., additional, Lee, K. S., additional, Joo, J. K., additional, Son, J. B., additional, Choi, J. R., additional, Vidali, A., additional, Barad, D. H., additional, Gleicher, N., additional, Sayyah-Melli, M., additional, and Kazemi-Shishvan, M., additional

Published
2011
Full Text
View/download PDF

29. Nonsupplemented luteal phase characteristics after the administration of recombinant human chorionic gonadotropin, recombinant luteinizing hormone, or gonadotropin-releasing hormone (GnRH) agonist to induce final oocyte maturation in in vitro fertilization patients after ovarian stimulation with recombinant follicle-stimulating hormone and GnRH antagonist cotreatment

Author

Macklon, N.S. (Nick), Eijkemans, M.J.C. (René), Ludwig, M. (Michael), Felberbaum, R.E., Diedrich, K., Bustion, S., Loumaye, E., Fauser, B.C.J.M. (Bart), Beckers, N.G.M. (Nicole), Macklon, N.S. (Nick), Eijkemans, M.J.C. (René), Ludwig, M. (Michael), Felberbaum, R.E., Diedrich, K., Bustion, S., Loumaye, E., Fauser, B.C.J.M. (Bart), and Beckers, N.G.M. (Nicole)

Abstract

Replacing GnRH agonist cotreatment for the prevention of a premature rise in LH during ovarian stimulation for in vitro fertilization (IVF) by the late follicular phase administration of GnRH antagonist may render supplementation of the luteal phase redundant, because of the known rapid recovery of pituitary function after antagonist cessation. This randomized two-center study was performed to compare nonsupplemented luteal phase characteristics after three different strategies for inducing final oocyte maturation. Forty patients underwent ovarian stimulation using recombinant (r-)FSH (150 IU/d, fixed) combined with a GnRH antagonist (antide; 1 mg/d) during the late follicular phase. When at least one follicle above 18 mm was observed, patients were randomized to induce oocyte maturation by a single injection of either r-human (h)CG (250 microg) (n = 11), r-LH (1 mg) (n = 13), or GnRH agonist (triptorelin; 0.2 mg) (n = 15). Retrieved oocytes were fertilized by either IVF or intracytoplasmatic sperm injection, depending on sperm quality. Embryo transfer was performed 3-4 d after oocyte retrieval. No luteal support was provided. Serum concentrations of FSH, LH, estradiol (E(2)), progesterone (P), and hCG were assessed at fixed intervals during the follicular and luteal phase. The median duration of the luteal phase was 13, 10, and 9 d for the r-hCG, the r-LH, and the GnRH agonist group, respectively (P = 0.005). The median area under the curve per day (from 4 d post randomization until the onset of menses) for LH was 0.50, 2.34, and 1.07 for the r-hCG, the r-LH, and the GnRH agonist group, respectively (P = 0.001). The median area under the curve per day for P was 269 vs. 41 and 16 for the r-hCG, the r-LH, and the GnRH agonist group, respectively (P < 0.001). Low pregnancy rates (overall, 7.5%; range, 0-18% per started cycle) were observed in all groups. In conclusion, the nonsupplemented luteal phase was insufficient in all three groups. In the patients receiving r-h

Published
2003

37. A regression model for the rate of success of in vitro fertilization.

Author

UCL - MD/MINT - Département de médecine interne, Baeten, S., Bouckaert, André, Loumaye, E., Thomas, Karl, UCL - MD/MINT - Département de médecine interne, Baeten, S., Bouckaert, André, Loumaye, E., and Thomas, Karl

Abstract

The treatment of infertility by in vitro fertilization involves several aspects of human reproductive physiology. Since failures are still numerous and since improved techniques are becoming increasingly available, it is important to develop a model where the components of success are identified, allowing estimation of the occurrence of these components of success in the infertile population. The model of Speirs reduces these components to two: uterine receptivity and embryo viability. The probabilities of uterine receptivity and embryo viability were estimated here in a retrospective study of patients in a Belgian hospital sample. For comparison, Australian and U.S. data were used. It was shown that the estimate of uterine receptivity for the Belgian sample is located between the estimates for Australian and U.S. samples. In view of the psychological problem of repeated unsuccessful attempts at in vitro fertilization in some patients, it is important to be able to single out some prognostic factors that would allow more precise estimation of the probability for success in each case. A regression method was developed for that purpose. Only the effect of age, in the Belgian sample, was found to influence uterine receptivity significantly.

Published
1993

38. [Invitro Fertilization At Cliniques-universitaires-saint-luc in Brussels (results From October 1986 To December 1989)]

Author

UCL - MD/GYPE - Département de gynécologie, d'obstétrique et de pédiatrie, Psalti, I., Bouckaert, André, Loumaye, E., de Cooman, Serge, Thomas, Karl, UCL - MD/GYPE - Département de gynécologie, d'obstétrique et de pédiatrie, Psalti, I., Bouckaert, André, Loumaye, E., de Cooman, Serge, and Thomas, Karl

Abstract

During this period, 591 patients were treated by in vitro fertilization (IVF) at the Cliniques Universitaires Saint-Luc in Brussels and 1 399 ovarian stimulation cycles, 1 242 retrievals, 968 transfers and 234 pregnancies were reported. There were 140 live deliveries. The outcome of IVF treatment cycles were evaluated according to woman's age, etiology of infertility, rank of cycle, quantities of oocytes and transferred embryos.

Published
1992

39. Rupture prématurée des membranes dans les grossesses multiples. Extraction active échoguidée du foetus et poursuite de la grossesse. A propos de deux cas.

Author

UCL - Autre, Billion, J M, Claudot, A, Loumaye, E., UCL - Autre, Billion, J M, Claudot, A, and Loumaye, E.

Abstract

Late miscarriage is a well-known complication in multiple pregnancies. Two cases were presented with rupture of the membranes and prolapse of the cord with the death of the presenting fetus are reported. In both cases extraction of the presenting fetus was carried out at 21 weeks of pregnancy followed by cervical cerclage. A triplet pregnancy which was reduced to two fetuses reached 30 weeks and two healthy infants were delivered. A twin pregnancy which was reduced to one fetus, resulted in that one being lost two weeks later when the patient developed chorioamnionitis and septicaemia.

Published
1991

40. Intérêt du dosage immunoradiométrique de l'hCG urinaire dans un programme de fécondation in vitro.

Author

UCL - Autre, Kalenga, M K, De Hertogh, René, Loumaye, E., Vankrieken, L., Thomas, Karl, UCL - Autre, Kalenga, M K, De Hertogh, René, Loumaye, E., Vankrieken, L., and Thomas, Karl

Abstract

Radio-immuno-assay estimations of urinary hCG were carried out with pharmacia Kit beta hCG Riact on 36 women who had received embryo transfers. The analysis was carried in order to try and find how and at what moment in time it is possible to diagnose very early a developing pregnancy after embryo transfer. In this work we have found that the mean level of urinary hCG was significantly higher (P less than 0.001) in women who became pregnant (group B) than in those who did not become pregnant (group A). The difference in mean hormone levels in these two groups became more marked in the following days. The time doubling of the hCG level varied between 1.21 and 3.24 days in group B. By the eighth day the level of urinary hCG was less in group B than in group A, probably due to rapid renal breakdown of hCG. In summary these results show that the level of urinary hCG estimated from the 11th day onwards after an embryo transfer repeated two or three days later makes it possible to detect early pregnancies.

Published
1991

41. Méthode mise au point pour le dosage et le monitoring de l'hCG urinaire.

Author

UCL, Kalenga, M K, De Hertogh, René, Loumaye, E., Vankrieken, L., Thomas, Karl, UCL, Kalenga, M K, De Hertogh, René, Loumaye, E., Vankrieken, L., and Thomas, Karl

Abstract

A kit of anti-beta hCG monoclonal antibodies (Pharmacia beta hCG Riact) has been tested in the assay and monitoring of urinary hCG. After several tests, the technique was found to be reproducible and specific for assay of hCG and showed good sensitivity in urine assays. Optimal sensitivity was seen in the urine pH range 5.5 and 10.00. Below 5.5 and above 10.00, its detection capacity dropped off sharply. Dilution of urine with the kit buffer gave hormonal values comparable to those of undiluted urine, but improved them substantially when the urine pH was below 5.5. It is therefore wise to dilute urine to avoid the potential risk of assay interference by urine acidity. In frozen urine, hCG concentrations tend to decrease but are not altered significantly. This recently developed method allows easy and reliable monitoring of urinary hCG for detection of unknown pregnancy in spontaneous cycles, surveillance of the state of embryos transferred during in vitro fertilization cycles, and evaluation of the efficacy of treatment of tumors secreting (beta hCG).

Published
1990

Catalog

Books, media, physical & digital resources
See catalog results